Research Article

Baseline Triglyceride Level Affected the Efficacy of Vildagliptin in Treating Type 2 Diabetes: A Post Hoc Analysis of the VISION Study

Table 1

Patients’ baseline demographics and clinical characteristics (FAS) according to the 3 TG-based tertiles.

Vildagliptin+metformin (VLDM)Metformin (HDM)
1st tertile
2nd tertile
3rd tertile
value1st tertile
2nd tertile
3rd tertile
value

Age (years)58 (11)57 (11)55 (11)<0.000158 (10)56 (12)55 (11)0.0555
Male, (%)462 (55.9)419 (49.0)479 (58.5)<0.000179 (45.9)73 (46.8)87 (56.1)0.1314
Weight (kg)67.2 (11.1)68.9 (10.8)71.7 (11.4)<0.000166.4 (10.4)68.7 (11.4)71.2 (12.2)0.0007
BMI (kg/m2)24.4 (3.1)25.1 (7.9)25.7 (3.1)<0.000124.6 (3.0)25.1 (3.4)25.6 (3.3)0.0119
Duration of DM (years)4.6 (4.5)4.1 (4.2)4.1 (3.9)0.03694.0 (4.3)3.8 (4.1)4.4 (4.4)0.4291
HbA1c (%)7.2 (0.9)7.2 (0.9)7.3 (0.9)0.03587.2 (0.8)7.2 (0.8)7.3 (0.8)0.5528
FPG (mmol/L)7.4 (1.9)7.5 (1.7)8.0 (2.0)<0.00017.3 (1.7)7.5 (1.6)7.8 (1.9)0.0225
120 min PPG (mmol/L)11.8 (3.6)12.6 (3.3)13.3 (3.8)0.01311.0 (3.5)12.8 (3.5)11.6 (3.8)0.1754
TG (mmol/L)0.95 (0.23)1.63 (0.21)3.44 (2.11)<0.00010.97 (0.21)1.62 (0.22)3.36 (2.12)<0.0001
Total cholesterol (mmol/L)4.37 (0.87)4.78 (0.83)5.04 (0.93)<0.00014.42 (0.90)4.88 (0.89)5.03 (0.98)<0.0001
SBP (mmHg)125 (11)126 (11)126 (11)0.1743125 (12)126 (12)127 (12)0.4498
DBP (mmHg)77 (8)77 (7)78 (8)0.003077 (7)77 (8)79 (7)0.0366
ALT (U/L)22 (13)26 (14)29 (15)<0.000121 (10)25 (13)28 (14)<0.0001
Plasma creatinine (μmol/L)64 (15)65 (16)66 (15)0.028664 (16)64 (15)66 (17)0.4972

All data except for the gender were in mean (standard deviation (SD)). FAS: full analysis set; VLDM: vildagliptin (50 mg bid) plus metformin (500 mg bid); HDM: metformin uptitration (1000 mg bid); 1st tertile:  mmol/L; 2nd tertile: ; 3rd tertile: ; TG: triglyceride; BMI: body mass index; FPG: fasting plasma glucose; 120 min PPG: 120-minute postprandial blood glucose; SBP: systolic blood pressure; DBP: diastolic blood pressure; ALT: alanine aminotransferase.